Hester Biosciences Ltd., one of India’s leading animal healthcare companies engaged in the manufacturing of vaccines and health products, has reported a strong financial performance for the third quarter of FY 2025–26.
On a standalone basis, the company recorded a net profit of ₹10.67 crore in Q3 FY26, marking a 140% year-on-year increase compared with ₹4.44 crore reported in the same quarter of the previous financial year.
Revenue from operations during the quarter stood at ₹70.35 crore, reflecting a 12% rise year-on-year from ₹62.86 crore in Q3 FY25.
The company also posted a significant improvement in operating performance. EBITDA for Q3 FY26 reached ₹17.75 crore, translating into an EBITDA margin of 25%, compared with ₹10.32 crore EBITDA and a 16% margin in the corresponding quarter last year. This represents a 72% increase in EBITDA on a year-on-year basis.
Earnings per share (EPS) for the quarter stood at ₹12.54.
Operational Developments
During the quarter, Hester Biosciences capitalised its fill-finish facility, effectively doubling the company’s drug product manufacturing capacity. The expanded facility is expected to provide greater operational flexibility and scalability, enabling the company to support rising demand across both domestic and export markets.
The company has also maintained strong operational discipline by keeping overheads under control, standardising manufacturing processes, and optimising manpower deployment.
Nine-Month Performance (9M FY26)
For the nine months ended December 2025, Hester Biosciences reported a standalone net profit of ₹25.72 crore, representing a 16% year-on-year growth from ₹22.21 crore in the corresponding period last year.
During the same period:
- EBITDA stood at ₹44.46 crore, with an EBITDA margin of 22%, compared with ₹40.95 crore EBITDA and a 20% margin in 9M FY25.
- Revenue from operations was reported at ₹198.42 crore, compared with ₹209.79 crore in the corresponding nine-month period of the previous financial year.
With enhanced production capacity and continued focus on operational efficiency, Hester Biosciences is positioning itself to support long-term growth in the animal healthcare sector across domestic and international markets.
